MEX3A is a diagnostic, independent prognostic biomarker and a promising therapeutic target in glioblastoma.

ABSTRACT:

Objective

Gliomas are the most common malignant brain tumors with a poor prognosis. Despite advances in molecular profiling, no targeted therapies significantly improve survival. Recently, it has been demonstrated that high expression of Muscle Excess 3A (MEX3A) correlates with poor overall survival (OS) in gliomas, generating interest in its potential as a biomarker and therapeutic target. This study analyzes the correlation between MEX3A expression and clinical-molecular features, assessing its diagnostic, prognostic, and therapeutic value in glioblastoma (GB), the most aggressive glioma subtype.

Methods

We performed a retrospective study on a consecutive series of surgically-treated glioma patients. The values of MEX3A mRNA levels for the discrete variables

SUBMITTER: Bufalieri F 

PROVIDER: S-EPMC12433882 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature